In this video, Nancy U. Lin, MD, discusses curative intent research in HER2-positive metastatic breast cancer.

The trial will test several treatment approaches in the maintenance setting for extensive stage small cell lung cancer.

The firm will test gedatolisib as a first-line treatment in patients with HR-positive, HER2-negative advanced breast cancer who are endocrine therapy resistant.

To meet the requirements for FDA Breakthrough Device Designation, CDx Diagnostics submitted technical and clinical evidence ...

In the same vein as weather forecast models that predict developing storms, researchers have now developed a method to ...

Fatty liver disease, now termed MASLD, is increasingly prevalent, particularly among those with weight issues, diabetes, or ...

Panelists discuss the importance of vigilant, patient-centered monitoring for metastatic melanoma patients with high disease ...

A doctor has urged patients to proceed with caution when using cannabis during cancer immunotherapy and called for more ...

Using a novel method to analyze tumor growth rates, researchers at Fox Chase Cancer Center have provided the most in-depth ...

Using a novel method to analyze tumor growth rates, researchers at Fox Chase Cancer Center have provided the most in-depth assessment to date of how fast breast cancers grow in patients and how ...

Ipsen said it received European Union approval for its Cabometyx drug for previously treated advanced neuroendocrine tumors. The French pharmaceutical company said late Thursday that the approval was ...

The addition of retifanlimab to chemotherapy increased progression-free survival in patients with advanced squamous cell ...